XML 69 R52.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurement By Fair Value Hierarchy Level During the periods presented, there were no transfers between fair value hierarchical levels.
Fair Value Measurements At Reporting Date
Description
Balance at December 31,
2020
Quoted prices
in active
markets
Level 1
Significant
other observable
inputs
Level 2
Significant
unobservable
inputs
Level 3
Measured at
Net Asset Value
as a Practical
Expedient (2)
(amounts in thousands)
Liabilities
Deferred compensation plan liabilities (1)
$33,474 $27,040 $— $— $6,434 
Interest rate cash flow hedge (3)
$2,439 $— $2,439 $— $— 
Description
Balance at December 31,
2019
Quoted prices
in active
markets
Level 1
Significant
other observable
inputs
Level 2
Significant
unobservable
inputs
Level 3
Measured at
Net Asset Value
as a Practical
Expedient (2)
(amounts in thousands)
Liabilities
Deferred compensation plan liabilities (1)
$33,229 $25,592 $— $— $7,637 
Interest rate cash flow hedge (3)
$189 $— $189 $— $— 
(1)The Company’s deferred compensation liability, which is included in other long-term liabilities, is recorded at fair value on a recurring basis. The unfunded plan allows participants to hypothetically invest in various specified investment options.
(2)The fair value of underlying investments in collective trust funds is determined using the net asset value (“NAV”) provided by the administrator of the fund as a practical expedient. The NAV is determined by each fund’s trustee based upon the fair value of the underlying assets owned by the fund, less liabilities, divided by outstanding units. In accordance with appropriate accounting guidance, these investments have not been classified in the fair value hierarchy.
(3)The Company's interest rate collar, which is included in other long-term liabilities, is recorded at fair value on a recurring basis. The derivatives are not exchange listed and therefore the fair value is estimated using models that reflect the contractual terms of the derivative, yield curves, and the credit quality of the counterparties. The models also incorporate the Company's creditworthiness in order to appropriately reflect non-performance risk. Inputs are generally observable and do not contain a high level of subjectivity.
Schedule Of Carrying Value Of Financial Instruments The following table presents the carrying value of financial instruments and, where practicable, the fair value as of the periods indicated:
December 31,
2020
December 31,
2019
Carrying
Value
Fair
Value
Carrying
Value
Fair
Value
(amounts in thousands)
Term B Loans (1)
$754,006 $737,041 $770,000 $774,813 
Revolver (2)
$114,727 $114,727 $117,000 $117,000 
Senior Notes (3)
$400,000 $398,000 $400,000 $423,250 
Notes (4)$425,000 $429,250 $425,000 $454,750 
Other debt (5)
$808 $873 
Letters of credit (5)
$6,229 $5,862 
The following methods and assumptions were used to estimate the fair value of financial instruments:
(1)The Company’s determination of the fair value of the Term B-2 Loan was based on quoted prices for these instruments and is considered a Level 2 measurement as the pricing inputs are other than quoted prices in active markets.
(2)The fair value of the Revolver was considered to approximate the carrying value as the interest payments are based on LIBOR rates that reset periodically. The Revolver is considered a Level 2 measurement as the pricing inputs are other than quoted prices in active markets.
(3)The Company utilizes a Level 2 valuation input based upon the market trading prices of the Senior Notes to compute the fair value as these Senior Notes are traded in the debt securities market. The Senior Notes are considered a Level 2 measurement as the pricing inputs are other than quoted prices in active markets.
(4)The Company utilizes a Level 2 valuation input based upon the market trading prices of the Notes to compute the fair value as these Notes are traded in the debt securities market. The Notes are considered a Level 2 measurement as the pricing inputs are other than quoted prices in active markets.
(5)The Company does not believe it is practicable to estimate the fair value of the other debt or the outstanding standby letters of credit.
Schedule of Cost Method Investments The following table presents the Company’s investments valued under the measurement alternative: 
Investments Valued Under the
Measurement Alternative
December 31,
20202019
(amounts in thousands)
Investment balance before cumulative impairment as of January 1,
$3,305 $11,205 
Accumulated impairment as of January 1,
— — 
Investment beginning balance after cumulative impairment as of January 1,
3,305 11,205 
Removal of investment in connection with step acquisition— (9,700)
Acquisition of interest in a privately held company— 1,800 
Ending period balance$3,305 $3,305